Synthesis of N-(3-arylprop-2-ynyl)substituted olanzapine derivatives as potential inhibitors of PDE4B by Babu, P. Vijaya et al.
Accepted Manuscript
Synthesis of N-(3-arylprop-2-ynyl)substituted olanzapine derivatives as poten-
tial inhibitors of PDE4B
P. Vijaya Babu, Dhilli Rao Gorja, Chandana Lakshmi T. Meda, Girdhar Singh
Deora, Sunder Kumar Kolli, Kishore V.L. Parsa, K. Mukkanti, Manojit Pal
PII: S0040-4039(14)00596-6
DOI: http://dx.doi.org/10.1016/j.tetlet.2014.04.009
Reference: TETL 44471
To appear in: Tetrahedron Letters
Received Date: 7 March 2014
Revised Date: 2 April 2014
Accepted Date: 3 April 2014
Please cite this article as: Vijaya Babu, P., Gorja, D.R., Meda, C.L.T., Deora, G.S., Kolli, S.K., Parsa, K.V.L.,
Mukkanti, K., Pal, M., Synthesis of N-(3-arylprop-2-ynyl)substituted olanzapine derivatives as potential inhibitors
of PDE4B, Tetrahedron Letters (2014), doi: http://dx.doi.org/10.1016/j.tetlet.2014.04.009
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  
1 
 
 
Graphical Abstract 
To create your abstract, type over the instructions in the template box below. 
Fonts or abstract dimensions should not be changed or altered. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Synthesis of N-(3-arylprop-2-ynyl)substituted olanzapine  
derivatives as potential inhibitors of PDE4B  
P. Vijaya Babu, Dhilli Rao Gorja, Chandana Lakshmi T.  
Meda, Girdhar Singh Deora, Sunder Kumar Kolli, Kishore V. L. Parsa, K. Mukkanti, Manojit Pal* 
 
N
N
S
N
N Cl
HN
S
O
O
Olanzapine
PDE4B
(atypical
antipsychotic)
 
 
Leave this area blank for abstract info. 
  
2 
 
Synthesis of N-(3-arylprop-2-ynyl)substituted olanzapine derivatives as potential inhibitors 
of PDE4B 
P. Vijaya Babu,a,b Dhilli Rao Gorja,a,b Chandana Lakshmi T. Meda,a Girdhar Singh Deora,c 
Sunder Kumar Kolli,d Kishore V. L. Parsa,a K. Mukkanti,b Manojit Pala,* 
 
aDr. Reddy’s Institute of Life Sciences, University of Hyderabad Campus, Gachibowli, 
Hyderabad 500046, India. 
bChemistry Division, Institute of Science and Technology, JNT University, Kukatpally, 
Hyderabad 500072, India. 
cThe University of Queensland, School of Pharmacy, Brisbane, QLD 4072, Australia. 
dDepartment of Chemistry, Acharya Nagarjuna University, Guntur 522510, Andhra Pradesh, 
India. 
 
--------------------------------------------------------------------------------------------------------------------- 
Abstract: The linkage between dopamine D2 receptors and PDE activity via cAMP prompted us 
to design a series of novel N-(3-arylprop-2-ynyl)substituted olanzapine derivatives as potential 
inhibitors of PDE4B. The target compounds were conveniently prepared by using a simple and 
inexpensive method involving Pd/C-mediated C-C bond forming reaction under Sonogashira 
conditions.  A number of compounds were synthesized by using this strategy in good yields. 
Some of the compounds showed promising inhibition of PDE4B when tested in vitro that was 
supported by the docking studies.   
Keywords: olanzapine, alkyne, PDE4, docking 
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Schizophrenia being a complex neuropsychiatric disorder is characterized by abnormalities in the 
perception of reality1 and affects approximately 1% of the adult population worldwide.2,3 The 
antipsychotic medications are the mainstay of treatment for most schizophrenic patients and can 
be classified into two major classes e.g. conventional (typical) and novel (atypical) neuroleptic 
drugs. These drugs mainly suppress dopamine and sometimes serotonin receptor activities. 
Clozapine that belongs to the atypical class is a debenzepine based antipsychotic and was found 
to be superior over other common antipsychotics.4 Its binding to the D-2, D-4, 5-HT2A and 5-
HT2C along with D-1, α-1, α-2, M-1 and H-1 receptors was found to be beneficial.5 A 
structurally close analogue of clozapine called olanzapine (zyprexa) belonging to the 
thienobenzodiazepine class has also been developed and found to possess similar 
pharmacological properties.6 While useful in treating some aspects of schizophrenia recent 
studies have suggested that currently available antipsychotic medications still possess 
considerable limitations. One of the many drug strategies that have been proposed in recent years 
is based on the fact that members of the phosphodiesterase (PDE) gene family may play a role in 
the treatment of schizophrenia.7a For example antipsychotic drugs are known to function through 
antagonism (blockade) of D2 dopamine receptors which in turn causes an increase level of 
cAMP (Fig. 1). This is also the outcome of inhibition of PDEs, a family of enzymes that degrade 
cyclic nucleotides (Fig. 1). This linkage between dopamine D2 receptors and PDE activity via 
cAMP is the basis for a possible therapeutic potential for PDE inhibitors in schizophrenia.7b 
Indeed, increasing evidences suggest that inhibition of PDE especially PDE4 and PDE10 can be 
beneficial for treating the positive, negative or cognitive symptoms associated with 
schizophrenia.7  
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Fig. 1. Increase of cAMP levels by antipsychotic medication and inhibition of PDE:7b The 
activity of enzyme adenylyl cyclase (AC) is increased by G protein-coupled D1-type dopamine 
receptors and decreased by D2 dopamine receptors. The antipsychotic drugs (believed to be 
antagonist of the D2 dopamine receptor) increase AC activity and the AC converts ATP to 
cAMP. The cAMP levels are controlled by PDEs via degrading the cAMP molecule to 5′-AMP. 
Inhibition of PDE activity by its inhibitors increases cAMP levels.  
 
Baesd on these observations and the fact that atypical antipsychotics including olanzapine (A, 
Fig. 2) have been used as a first line therapy to treat schizophrenia, we decided to focus on the 
identification of new PDE4 inhibitors via structural modifications of olanzapine.8 A diverse class 
of compounds has been explored for the discovery of novel PDE4 inhibitors.9 For example, 
alkyne derivatives B (Fig. 2) has been reported as inhibitors of PDE4.10 Thus, we hypothesized 
that combining some of the structural features of A and B in a single molecule may lead to a new 
class of compound C (Figure 1) which may be explored for the identification of novel PDE4 
inhibitors11 thereby potential treatment of schizophrenia. We initially became interested in the 
synthesis of C and subsequent evaluation of their PDE4 inhibiting properties in vitro. 
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Fig. 2. Design of new PDE4 inhibitors (C) based on olazapione A and reported inhibitors B.  
 
The designed target compounds were conveniently prepared by using a Pd/C-mediated C-C bond 
forming reaction under Sonogashira type coupling conditions.12 The use of Pd/C–CuI–PPh3 as an 
alternative but inexpensive catalyst system for Sonogashira type coupling has gained 
considerable interest.12 The use of Pd/C as a catalyst offers several advantages. For example, 
Pd/C is stable, easy to handle and can be stored for a long period of time without taking any extra 
precautions. Additionally, it can be separated easily from the product via simple filtration and is 
recyclable. More importantly, in view of the use of Pd/C for hydrogenation in industrial scale for 
over more than 100 years the Pd/C mediated coupling reactions are amenable for large scale 
preparation. Thus, due to the simplicity, advantages and versatility of the Pd/C mediated C-C 
bond forming reactions we decided to explore this strategy for the synthesis of compound C (or 
4) as shown in Scheme 1. 
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Scheme 1. Synthesis of N-(3-phenylprop-2-ynyl)substituted olanzapine derivatives 4. 
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The key starting material i.e. the terminal alkyne 2 was synthesized by treating olanzapine (1) 
with propargyl bromide in the presence of NaH in THF (Scheme 1).13 Initially, the alkyne 2 was 
reacted with 4-chloro-2-iodoaniline 3a in the presence of 10%Pd/C-PPh3-CuI and Et3N in EtOH 
at 70°C for 6 h (entry 1, Table 1). The desired product 4a was isolated in 90% yield. An increase 
in reaction time did not improve the product yield (entry 2, Table 1) whereas change of base 
from Et3N to K2CO3 suppressed the product formation significantly (entry 3, Table 1). The 
reaction also did not afford 4a in good yield in the absence of Pd/C or CuI indicating their key 
role in the present reaction (entry 4 and 5, Table 1). The use of other Pd-catalyst e.g. 
Pd(PPh3)2Cl2 was also examined (entry 5, Table 1). While the reaction proceeded in this case the 
yield of product 4a was inferior to that of entry 1.  Thus the reaction condition of entry 1 was 
chosen for the further study.  
 
Table 1. Effect of reaction conditions on coupling of terminal alkyne 2 with 3a 
NH2
Cl
I
70oC,
N
N
N
S
N
H2N
Cl2
4a3a
Pd-cat
CuI
Base
EtOH
+
 
Entry Pd-catalysts Base Time (h) Yield b (%) 
1 10% Pd/C–PPh3 Et3N 6 90 
2 10% Pd/C–PPh3 Et3N 8 89 
3 10% Pd/C–PPh3 K2CO3 10 10 
4 PPh3c Et3N 10 9 
5 10% Pd/C–PPh3d Et3N 8 10 
6 Pd(PPh3)2Cl2 Et3N 6 60 
aAll reactions were carried out using 2 (1 equiv), alkyne 3a (1 equiv), a Pd-catalyst (0.016 
equiv), PPh3 (0.125 equiv), CuI (0.02 equiv), and a base (2 equiv) in EtOH (5.0 mL), at 70 °C. 
bIsolated yield. cThe reaction was carried out without Pd/C. dThe reaction was carried out 
without CuI. 
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We then prepared a small library of compounds using the optimized conditions (Table 2).  A 
number of iodoarenes (3) were coupled with the alkyne 2 in the presence of 10%Pd/C-PPh3-CuI 
to give the desired products 4 in acceptable to good yield.14 Notably, a shorter reaction time was 
applied in the case of iodoarene 3d and 3h to avoid the further intramolecular cyclization of the 
alkyne 4d and 4h generated in situ.8  
 
Table 2. Pd/C-mediated synthesis of N-(3-arylprop-2-ynyl)substituted olanzapine derivatives 
(4).a 
Entry Iodoarene (3) Time (h) Product (4)  Yieldb (%) 
1 
NH2
I
Cl
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6 SN
N
N
N
NH2
Cl 4a 
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2 
NH2
I
Br
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N
N
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85 
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aAll reactions were carried out using 2 (1 equiv.), alkyne 3 (1 equiv.), 10% Pd/C (0.016 equiv.), 
PPh3 (0.125 equiv.), CuI (0.02 equiv.), and Et3N (2 equiv.) in EtOH (5.0 mL), at 70 °C. bIsolated 
yield. 
 
The PDE4B inhibitory potential of all the synthesized compounds were assessed in vitro at 
30 µM by using a PDE4B enzyme assay15 (Table 3). Rolipram16 a well known PDE4 
inhibitor was used as a reference compound in this assay. Compounds that showed inhibition 
greater than 50% were considered as promising inhibitors. Accordingly, compounds 4c, 4d, 
4g and 4h were identified as hit molecules and 4h that showed ~ 63% inhibition was found to 
be the best. While rolipram showed ~ 88% inhibition the parent compound olanzapine 
however did not show any PDE4 inhibitory properties. It is therefore evident from Table 3 
that a non PDE4 inhibitor olanzapine has been converted into PDE inhibitors via introducing 
an appropriate 3-arylprop-2-ynyl moiety at its central ring nitrogen. It is also evident that an 
anilide moiety attached to the alkyne group played a key role in the inhibitory activities e.g. 
4g and 4h. In a dose response study the compound 4h showed inhibitory activities across all 
the dose tested (31, 23, 15 and 14% at 10, 3, 1 and 0.3 µM) indicating its potential as a PDE4 
7 
I
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inhibitor.   
 
Table 3. Inhibition of PDE4B by compound 4 at 30 uM.   
 
Entry Compounds 
Average % 
inhibition 
 
SD 
 
1.  4a 27.21 1.72  
2.  4b 22.57 2.10  
3.  4c 50.15 1.82  
4.  4d 60.56 2.43  
5.  4e 28.43 3.12  
6.  4f 26.68 2.90  
7.  4g 59.52 0.87  
8.  4h 63.11 1.09  
9.  Rolipram  88.01 0.09  
SD = standard deviation 
 
We then performed PDE4B docking studies using compounds 4c, 4g, and 4h to understand 
the nature of interactions of these molecules with this protien in silico. The docking analysis 
of these molecules was carried out using Maestro, version 9.217 implemented from 
Schrödinger molecular modeling suite. The structural coordinates of Phosphodiesterase 4B 
(PDB ID: 1XMY)18 were obtained from the protein data bank (PDB). The GLIDE scores 
obtained after docking of these molecules with PDE4B protein are summarized in Table 4. 
The data shown in Table 4 clearly suggests that these molecules bind well with the PDE4B 
whereas the compound 4h is best among them. Thus, the sulfonamide NH of 4h participated 
in two H-bond interactions with Asp 392 and Thr 345 whereas the benzene ring of the 
benzenesulfonamide moiety participated in a pi-pi stacking with Hie 234 (Fig. 3, For binding 
orientation of 4h at the inhibitor binding pocket of PDE4B, see: Fig. S-4 and S-5, ESI). A H-
bond interaction with Tyr 233 and two pi-pi stacking with Tyr 233 and Phe 446 were observed 
in case of 4g (see Fig. S-2, ESI). The amino group of 4c showed one H-bonding with Asp 
392 of PDE4B (see Fig. S-3, ESI).  
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Table 4: Glide score and contributing XP parameters. 
Compound  GScore LipophilicEvdW PhobEn HBond Electro 
4h -8.36 -5.62 -1.34 -0.89 -0.34 
4g -8.11 -5.51 -1.62 -0.70 -0.28 
4c -5.89 -6.03 -1.37 -0.32 -0.82 
Rolipram -11.09 -4.65 -1.98 -1.49 -0.51 
GScore: glide score 
LipophilicEvdW: Chemscore lipophilic pair term and fraction of the total protein-ligand vdw energy 
HBond: Rewards for hydrogen bonding interaction between ligand and protein 
PhobEn: Hydrophobic enclosure reward 
Electro: Electrostatic reward 
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Fig. 3. Binding mode and interactions of 4h at the inhibitor binding site of PDE4B. 
In conclusion, for the first time N-(3-arylprop-2-ynyl)substituted olanzapine derivatives have 
been designed and synthesized by using Pd/C-Cu mediated C-C bond forming reaction. One 
compound showed PDE4B inhibitory properties in vitro and good interactions with PDE4B 
protein in silico. Since linkage between dopamine D2 receptors and PDE activity via cAMP 
can be the basis for a possible therapeutic potential for PDE inhibitors in schizophrenia, the 
present class of olanzapine derivatives has medicinal value. The strategy presented here has 
potential for the discovery of novel PDE4 inhibitors. 
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